Montalban X, et al. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Primary Progressive Multiple Sclerosis in the ORATORIO Trial. PR2086. EAN 2017.
MIBG plus dinutuximab met of zonder vorinostat bij gerecidiveerd/refractair neuroblastoom
sep 2025 | Neuro-oncologie